Uterine Fibroids Market Overview & Growth Outlook
The Gloabal Uterine Fibroids Market—benign smooth‑muscle tumors—affect an estimated 60–80% of women of reproductive age, with many remaining asymptomatic while others experience heavy bleeding, pain, or fertility issues. The global treatment market, including drug therapies and device-based interventions, is poised for strong growth: most estimates place market size at around USD 5 billion in 2024–2025, with projected values ranging from USD 7.5 billion to over USD 9 billion by 2030, depending on segmentation and scope .
The uterine fibroids treatment devices segment, specifically, is expected to grow at a CAGR of 9–9.4%, rising from ~USD 7 billion in 2024 to USD 12.1 billion by 2030. Devices dominate in North America (approx. 48% share) and will see the fastest expansion in Asia Pacific (~10.2% CAGR) due to rising awareness and better access to technologies .
🧩 Market Segmentation: Types of Treatments & Fibroid Variants
By Treatment Modality
Surgical procedures: hysterectomy and myomectomy remain prevalent and dominated ~34% share in 2024 .
Ablation techniques, including radiofrequency, cryoablation, hydrothermal or microwave, show the highest growth (up to ~10.4% CAGR) as they preserve fertility and reduce recovery time .
Non-invasive methods, notably MRI‑guided High‑Intensity Focused Ultrasound (MR‑HIFU), are gathering traction as patient preference shifts; in the U.S., non‑invasive segment leads in growth rate .
By Device Type
Instruments and consumables constitute the largest category in devices (~instruments largest share in 2023) .
Minimally invasive (laparoscopic, robotic‑assisted, ablation) and non-invasive treatments are expanding rapidly.
By Drug Therapy Class (pharmaceutical treatment segment):
GnRH antagonists (e.g. relugolix combination therapy such as Myfembree®, Ryeqo®) are widely adopted for heavy menstrual bleeding in fibroid patients, approved in U.S. (since May 2021) and EU in 2021 .
Investigational therapies, like merigolix (in phase 2 trials as of late 2024) may further diversify drug‑based management .
Other pharmacologic categories include progestins, GnRH agonists, and SPRMs.
Grab PDF Guide - https://www.theinsightpartners.com/sample/TIPRE00024418
By Fibroid Type
Segmented into submucosal, intramural, subserosal, and pedunculated fibroids—with submucosal expected to dominate treatment volumes due to their symptomatic profile .
By End‑User Setting
Includes hospitals, specialty clinics, and ambulatory surgical centers. Most devices are used in hospitals or ASC settings, while drug therapies are administered via outpatient clinics and retail pharmacies .
🏆 Leading Companies & Competitive Landscape
Device & MedTech Leaders
Among device manufacturers, key players include Medtronic, Boston Scientific, Insightec, Hologic (now including Gynesonics’ Sonata system following its 2025 acquisition), CooperSurgical, Stryker, Conmed, Merit Medical, Karl Storz, Olympus, Johnson & Johnson (Ethicon) and others ~ collectively commanding ~35% of market share .
In Jan 2025 Hologic acquired Gynesonics (~USD 350 M), securing the Sonata transcervical radiofrequency ablation platform—an incisionless option navigated with intrauterine ultrasound, positioned to drive growth in uterus‑preserving care .
Insightec, Philips/Profound Medical produce MR‑guided HIFU systems (e.g. Sonalleve) gaining CE‑mark approval worldwide and pending or under trial in U.S. for non‑invasive fibroid ablation .
Pharma Players in Drug Therapies
Leading pharmaceutical names include Pfizer (in partnership with Myovant Sciences, marketing Myfembree/Ryeqo), AbbVie, AstraZeneca, Kissei (Linzagolix), Theramex, Bayer, and others working on SPRMs or GnRH antagonists .
Recent approvals and international licensing (e.g. Ryeqo in Canada via Pfizer‑Sumitomo deal early 2024) further consolidate their reach .
🚀 Growth Strategies & Market Drivers
1. Innovation & Technology Differentiation
Development of minimally invasive and non‑invasive platforms (e.g. Sonata, MR‑HIFU) that preserve fertility and shorten recovery is a core focus .
Investment in smart, connected devices, real‑time analytics, and integration with digital health platforms is emerging as a strategic frontier .
2. Regulatory Approvals & Product Launches
Regulatory clearance (FDA, CE‑Mark) for combination drugs (relugolix combos) or devices (e.g. HIFU platforms) enables entry into new geographies.
Launch cycles, like Hologic’s release of Smart OS 2.4 software for Sonata in late 2024, improve procedural performance and provider uptake .
3. Mergers, Acquisitions & Partnerships
Hologic’s acquisition of Gynesonics (2025) is a prime example of consolidation to capture innovative platforms.
Partnerships between pharma firms and regional license holders (e.g. Pfizer/Sumitomo in Canada) and research collaborations are common .
4. Geographic Expansion & Market Penetration
While North America remains dominant due to infrastructure and awareness (~48% share in devices), Asia‑Pacific is fastest–growing (~10 %+ CAGR) aided by rising incomes, improved diagnosis rates, and expanding healthcare access .
Emerging regional players in Latin America, Middle East/Africa, and India are offering cost‑effective device options to expand coverage .
5. Awareness Campaigns & Medical Education
Patient and provider education campaigns (e.g. fibroid awareness initiatives in the U.S.) drive early diagnosis and demand for less invasive treatments .
Emphasis on fertility preservation and personalized medicine supports adoption of alternatives to hysterectomy .
🔍 Segment Performance & Opportunity Areas
Surgical vs Minimally/Non‑Invasive
Traditional surgery (hysterectomy/myomectomy) remains significant but is stagnant or declining share-wise due to shifts toward fertility-conserving methods.
Ablation and non‑invasive methods are gaining share quickly: ablation CAGR ~10.4%, non‑invasive fastest in U.S. segment growth .
Device vs Drug Markets
Combined device and drug markets are both expanding; devices larger in absolute size (~USD 7 billion in 2024) and drug therapies growing faster (~10%+ CAGR) albeit from a smaller base (~USD 2 billion drug market in 2023/24) .
Fibroid types & demographics
Submucosal fibroids, followed by intramural, represent the most treated subtypes due to their symptomatic burden and fertility impact . Tailored strategies aimed at ethnic groups (e.g. African‑American women in the U.S., South Asian populations) are emerging as important demographics .
End‑User Channels
Hospitals and specialty centers remain key for high-end interventions, while ambulatory surgical centers and outpatient clinics drive volume for minimally invasive procedures and drug dispensing.
🧠 Strategic Recommendations
Focus on fertility‑sparing innovation (e.g. Sonata, HIFU): market differentiation via lower‑risk, outpatient, uterus‑preserving solutions.
Expand geographic footprint in Asia & emerging markets with tailored pricing, partnerships, and awareness programs.
Pursue vertical integration or strategic partners (M&A in devices; licensing or clinical alliances in drugs) to accelerate scale.
Emphasize digital health capabilities: apps, connected platforms for tracking post‑procedure outcomes and device performance.
Engage in patient/provider education campaigns, emphasizing minimally invasive and medical alternatives to hysterectomy to shift standard of care.
Segment coverage by fibroid type and demographic groups, aligning therapies to targeted patient needs and regional disease prevalence.
✅ Final Takeaways
The uterine fibroids treatment market—comprising medical drugs, device‑based therapies, surgical procedures—is growing robustly at 7–10% CAGR, with forecasts projecting USD 7–12 billion+ values across sub‑segments by 2030.
Device segment alone is projected to reach around USD 12 billion by 2030, driven by minimally invasive and non‑invasive technologies, particularly in North America and Asia‑Pacific .
Top players include Medtronic, Boston Scientific, Insightec, Hologic (Gynesonics Sonata), Pfizer/Myovant, AbbVie, AstraZeneca, Bayer, CooperSurgical and more.
Key growth levers: innovation in surgical/device tech, new drug approvals, geographic expansion, mergers & partnerships, and investments in awareness and tailored education.
Segmentation insights: ablation and non-invasive treatments growing fast; submucosal/intramural fibroids dominant; hospitals/ASCs primary channels; drug therapies are rising in importance.
As patient awareness and medical options continue to expand, stakeholders prioritizing innovation, partnerships, and patient‑centric models are well placed to capture leadership in this evolving fibroid therapy landscape.
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Comments
Post a Comment